Skip to main content
Premium Trial:

Request an Annual Quote

Guardant Health Licenses Genomic Cancer Assays to Adicon for Testing in China

NEW YORK – Guardant Health and Chinese clinical laboratory firm Adicon said on Wednesday that they have signed a strategic partnership under which Adicon has licensed Guardant's tissue and blood-based genomic cancer assays, which it will now be able to offer to biopharmaceutical companies conducting clinical trials in China.

Financial terms of the agreement were not disclosed. The deal includes Guardant's liquid biopsy assays Guardant360 and GuardantOmni, the more recently launched Guardant360 TissueNext, and the firm's minimal residual disease test Guardant Reveal.

According to Adicon CFO Lawrence Wang, cancer has become a higher priority in China in recent years due to increasing incidence rates. "With our CAP-accredited laboratory in Shanghai, we are delighted to partner with Guardant Health to make its cancer tests available for biopharmaceutical partners," he said in a statement.

The firms said that more than 4.5 million people in China were diagnosed with cancer in 2020, and 3 million died from the disease, making it the leading cause of death in the country.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.